The three IL-1 blockers that have been tested so far (anakinra, canakinumab, and rilonacept) have all been proven effective and safe, although only canakinumab is currently approved for use in so-JIA (127–130). The gene discussed is IL1B; the disease is juvenile idiopathic arthritis.